Effects of ischemia-reperfusion on the absorption and esterase metabolism of diltiazem in rat intestine.
Intestinal ischemia-reperfusion (I/R) is a serious clinical condition that triggers a complex inflammatory response. Inflammatory processes affect some enzymatic systems related to intestinal drug metabolism and bioavailability. Diltiazem (DTZ) is a calcium channel blocker, which is extensively metabolised in the intestine by esterases and different CYP450 isoforms. The main biotransformation pathway of DTZ in rats is desacetylation by esterases. This study analysed the effect of I/R on intestinal absorption and metabolism of DTZ, focusing on esterase activity, through different methodologies, after 60 min of superior mesenteric artery occlusion and 30 min of reperfusion or sham surgical procedures. The rate of DTZ appearance in blood during in situ studies increased significantly in the I/R group (0.094+/-0.014 10(-5) cm/s vs 0.271+/-0.110 10(-5) cm/s) and the calculated metabolised fraction of DTZ decreased significantly, showing an important reduction in the desacetylase activity in the I/R group. These results were supported by microsomal incubations, where desacetylase activity was related to esterases by specific inhibition, using paraoxon and bis-nitrophenylphosphate, and also by studies in everted rings. DTZ metabolism was higher in the jejunum than in the ileum, the esterase activity being affected by I/R in both regions. The present findings suggest that I/R injury clearly affects the esterases' activity and modifies the amount of DTZ and its metabolites in blood during in situ perfusion. This modification of intestinal esterase activity could be important for the pharmacokinetic behaviour of other drugs and prodrugs after intestinal pathologies involving inflammation and oxidative stress.
Molina
Antonio J
AJ
Department of Physiology, University of Leon, Campus de Vegazana s/n, 24071 Leon, Spain.
Prieto
Julio G
JG
Merino
Gracia
G
Mendoza
Gracia
G
Real
Rebeca
R
Pulido
Mivis M
MM
Alvarez
Ana I
AI
D000818:Animals; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D004110:Diltiazem / Q000493:pharmacokinetics*; D004950:Esterases / Q000378:metabolism*; D008658:Inactivation, Metabolic; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000098:blood supply / Q000201:enzymology / Q000473:pathology; D008297:Male; D008861:Microsomes / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology
D002121:Calcium Channel Blockers; D004950:Esterases; D004110:Diltiazem